Table 2. Cox Proportional Hazards Regression Analysis Evaluating the Risk of an Unfavorable Event During Treatment Period.
| Baseline Parameter | Hazard Ratio (95% CI) | P Value |
|---|---|---|
| Daily regimena | 0.310 (0.131-0.733) | .008 |
| Part-daily regimen | 0.834 (0.440-1.578) | .58 |
| Baseline CD4 lymphocyte count <100 cells/μL | 0.903 (0.496-1.644) | .74 |
| Sputum culture grade >2+ | 1.476 (0.817-2.667) | .20 |
| Isoniazid resistance at baselineb | 2.340 (1.107-4.947) | .03 |
| Baseline weight, kg | 0.961 (0.924-1.000) | .05 |
| Baseline viral load, log10 copies/mL | 1.363 (0.995-1.866) | .05 |
| Radiographic involvement >3 zones | 0.906 (0.479-1.714) | .76 |
| Receiving ART at initiation of ATT | 1.113 (0.530-2.340) | .78 |
Abbreviations: ART, antiretroviral therapy; ATT, antituberculosis therapy.
a
The hazard of an unfavorable response was reduced to one-third when a daily regimen replaced an intermittent regimen.
b
The hazard of an unfavorable response increased 2.3 times when there was isoniazid resistance at baseline.